



Gastric Cancer Factsheet: Insights & Key Developments

Key Insights on Gastric Cancer Care and Infrastructure

Core Pillars:

- 1. Infrastructure
- 2. Treatment Access, Research Funding and Awareness Campaigns
- 3. Survival Rates, Early Detection and Palliative Care
- 4. Utilization of Biomarkers
- 5. Clinical Guidelines
- 6. Reimbursement
- 7. Gastric Cancer Screening

Gastric cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.

This factsheet provides a comprehensive overview of key pillars shaping Gastric cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- Incidence share: Gastric cancer is in the top 5 digestive cancers, but not among the top male cancers.
- Incidence rate: Approximately 12 per 100,000 total population.
- Total new cases (2022): Estimated ~3,355 cases in both sexes.
- Daily diagnoses: About 9 people per day.
- Deaths (2022): Around ~1,900 deaths.
- 5-year survival rate: Estimated < 40%.
- Most affected age group: Primarily individuals aged 60+.
- Screening participation: Virtually none; most diagnosis at advanced stages.





- Public and private healthcare sectors offer access to cancer care, including oncology units in urban tertiary hospitals.
- National Cancer Institute and regional oncology centers are equipped with pathology and endoscopic services.

0

Opportunity

- Investment in regional cancer centers under the National Cancer Plan.
- Telemedicine expansion could bridge gaps in pathology and follow-up for remote patients.



- Significant regional disparities: rural areas lack consistent access to diagnostic imaging and endoscopy.
- Infrastructure strain in public hospitals leads to delays in care for lowerincome patients.

Threats

sustainability.

• Earthquake-prone zones

and medical equipment

• Overreliance on urban

centers for specialized

care creates bottlenecks.

threaten hospital resilience

- 5. Advanced nationwide infrastructure, widespread availability in public and private sectors, integration with clinical practice.
- 4. Strong infrastructure in major hospitals and cancer centers, some regional disparities.
- 3. Moderate infrastructure, primarily in private settings or research institutions.



2. Limited infrastructure, available only in select centers or for high-cost private testing.



1. Minimal or no infrastructure, testing mostly unavailable or sent abroad.

Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
South Africa	0	<u> </u>
Kenya	0	
Nigeria	0	
Egypt	0	<u> </u>
Morocco		
Algeria		
Ethiopia		
India	0	
Japan	0	
South Korea		
China	0	
Thailand	<u> </u>	<u> </u>
Singapore		
United Kingdom	0	
Germany		
France		
Netherlands		0
Sweden		
Italy		0
Spain		
Poland	0	0
Mexico		0
Brazil	0	0
Argentina	0	0
Chile	<u> </u>	<u> </u>
Colombia	0	0
United States		
Canada		
Australia		
New Zealand	0	
Greece	0	<u> </u>
Rwanda		
Uganda		
Serbia	<u> </u>	0
Saudi Arabia	0	
UAE	0	
Syria		
Indonesia	0	
Vietnam		
Philippines		
Russia		<u> </u>
Malaysia		



Chile

Treatment Access, Research Funding and Awareness Campaigns

S

0

W

Strengths

- GC is included in the country's Explicit Health Guarantees Plan (GES), mandating treatment access regardless of income.
- Awareness campaigns about H. pylori and stomach cancer are periodically supported by the Ministry of Health.

Opportunity

- Boosting national research funding could position Chile as a trial site for targeted therapies.
- Partnering with local NGOs for culturally relevant awareness drives in indigenous communities (e.g., Mapuche).

Weakness

- Limited number of gastric cancer-focused clinical trials or research compared to other cancers.
- Public awareness still low regarding early GC symptoms and the link with H. pylori.

Threats

- Inequity in drug access between private and public insurance holders.
- Competing priorities
 (e.g., COVID-19 recovery)
 may dilute focus on GC specific initiatives.

- 5. Strong healthcare infrastructure with comprehensive treatment access, high research funding, and nationwide awareness campaigns. Patients have access to advanced therapies, clinical trials, and widespread early detection programs.
- 4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.
- 3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.
- Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.
- 1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

			Carried Carried Control of the Carried	
	70-			
3				
				3.
				13 or 31
ess				
oer of er-focuse	ed	1	5	
or recogn				



Awareness

Campaigns

Research

Funding



Chile

Survival Rates, Early Detection and Palliative Care


Strengths

- Chile has one of the highest gastric cancer burdens in Latin America, which prompted earlier government response.
- Palliative care services are well-integrated into cancer hospitals in Santiago and other major cities.

0

Opportunity

- Early detection programs targeting high-risk groups in central and southern Chile.
- Expanding H. pylori eradication programs can reduce GC incidence significantly.



- Around 65-70% of GC cases are diagnosed at advanced or metastatic stages.
- 5-year survival remains low (~20-25%) due to late presentation and limited access to advanced therapies in public systems.

- Cultural stigmas and fear of cancer diagnosis delay patient presentation.
- Gaps in general practitioner awareness about referral criteria for endoscopy.

- 5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.
- 4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.
- 3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.
- 2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.
- 1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

Country	Survival Rates	Early Detection	Palliative Care
South Africa	0	0	0
Kenya			
Nigeria			
Egypt	0		
Morocco			
Algeria			
Ethiopia			
India	<u> </u>	0	<u> </u>
Japan			
South Korea			
China	0	0	0
Thailand	<u> </u>	<u> </u>	<u> </u>
Singapore			
United Kingdom			
Germany			
France			
Netherlands			
Sweden			
Italy			
Spain			
Poland		<u> </u>	\bigcirc
Mexico	<u> </u>	<u> </u>	<u> </u>
Brazil	<u> </u>	<u> </u>	<u> </u>
Argentina	<u> </u>	<u> </u>	<u> </u>
Chile	<u> </u>	<u> </u>	<u> </u>
Colombia	<u> </u>	<u> </u>	<u> </u>
United States			0
Canada			
Australia			
New Zealand			
Greece	0	0	0
Rwanda			
Uganda			
Serbia	<u> </u>	<u> </u>	<u> </u>
Saudi Arabia	<u> </u>	<u> </u>	<u> </u>
UAE	<u> </u>	<u> </u>	<u> </u>
Syria	_		
Indonesia	<u> </u>		0
Vietnam	<u> </u>	•	0
Philippines	0	•	0
Russia		0	0
Malaysia			



Chile *_ Utilization of Biomarkers

Strengths

testing and immunotherapy pathways.

Opportunity

- Biomarker-based personalized treatment can reduce costs from ineffective therapy in the long term.
- Introduction of national guidelines for biomarker use would promote consistency.

Weakness

2.6

- Lack of standardized access to newer biomarkers like CLDN18.2 and FGFR2b.
- MSI and dMMR testing is still not routine in most public hospitals.

Threats


- High costs and lack of reimbursement prevent biomarker uptake in many public settings.
- Shortage of molecular pathology labs and specialists outside major cities.

Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.

0.22

Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.

lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.



(CPS≥1)

dMMR



 HER2 testing is available in major oncology centers for advanced GC patients.

 Growing oncologist awareness of PD-L1

0







- National guidelines for cancer care are published and followed in leading hospitals.
- Protocols include
 HER2 testing for
 metastatic GC and
 access to
 trastuzumab.

0


Opportunity

- National update of GC guidelines could align with ESMO/ASCO and LATAM standards.
- Multidisciplinary tumor boards could improve decision-making at regional levels.

Weakness

- Clinical guidelines are often outdated or lack inclusion of recent therapies or markers.
- Limited training on newer therapies like immune checkpoint inhibitors.

- Fragmented adoption of guidelines between public and private institutions.
- Bureaucratic delays in guideline revision and implementation.



	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	0	*	*	*	*
Feasibility of Integration	0	×	×	×	×
Adoption of International Guidelines	0	*	*	*	*
Engagement with Updates	*	0	*	*	*
ESMO Guidelines Implementation	0	*	*	*	*





- GES coverage ensures GC treatment is a guaranteed benefit, including surgery and chemotherapy.
- Trastuzumab is reimbursed for HER2+ advanced GC under certain clinical indications.

0

Opportunity

- Health economics studies can demonstrate costeffectiveness of biomarker testing and targeted drugs.
- Expand GES coverage to include newer drugs for advanced GC.

Weakness

- Newer targeted therapies and advanced diagnostics (e.g., PD-L1, CLDN18.2 testing) often not reimbursed.
- Public insurance patients face more limitations in access than those with private ISAPRE coverage.

- Budget constraints and prioritization of more prevalent cancers reduce funding flexibility.
- Rising treatment costs could lead to tighter reimbursement controls.



- A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.
- A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as co-pays, limited coverage, or financial caps on testing.
- No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

United States United Kingdom Canada Australia Germany France Netherlands Sweden Italy Spain Poland Japan South Korea China India Singapore Thailand South Africa Egypt Morocco Algeria Ethiopia Mexico Brazil Argentina Chile Colombia Sueda Sueda Greece Rwanda Uganda Sueda	Country	Reimbursement Framework	No-cost Access
Canada ■ Australia ■ Germany ■ France ■ Netherlands ■ Sweden ■ Italy ■ Spain ■ Poland ■ Japan ■ South Korea ■ China ■ India ■ Singapore ■ Thailand ■ South Africa ■ Kenya ■ Nigeria ■ Egypt ■ Morocco ■ Algeria ■ Ethiopia ■ Mexico ■ Brazil ■ Argentina ■ Chile ■ Colombia ■ New Zealand ■ Greece ■ Rwanda ■ Uganda ■ Saudi Arabia ■	United States		0
Australia	United Kingdom		
Germany	Canada		
France	Australia		
Netherlands Sweden Italy Spain Poland Japan South Korea China India India Singapore Thailand South Africa Kenya Nigeria Egypt Morocco Algeria Ethiopia Mexico Brazil Argentina Chile Colombia New Zealand Greece Rwanda Uganda SudA Arabia UAE Syria Indonesia Vietnam Philippines Russia	Germany		
Sweden	France		
Italy	Netherlands		
Spain Image: spain state of the control o	Sweden		
Poland Image: Control of the polar of the p	Italy		
Japan ■ South Korea ■ China ■ India ■ Singapore ■ Thailand ■ South Africa ■ Kenya ■ Nigeria ■ Egypt ■ Morocco ■ Algeria ■ Ethiopia ■ Mexico ■ Brazil ■ Argentina ■ Chile ■ Colombia ■ New Zealand ■ Greece ■ Rwanda ■ Uganda ■ Serbia ■ Saudi Arabia ■ UAE ■ Syria ■ Indonesia ■ Vietnam ■ Philippines ■ Russia ■	Spain		
South Korea ● China ● India ● Singapore ● Thailand ● South Africa ● Kenya ● Nigeria ● Egypt ● Morocco ● Algeria ● Ethiopia ● Mexico ● Brazil ● Argentina ● Chile ● Colombia ● New Zealand ● Greece ● Rwanda ● Uganda ● Serbia ● Saudi Arabia ● UAE ● Syria ● Indonesia ● Vietnam ● Philippines ● Russia ●	Poland		
China India India India Singapore Indiand Thoiland Indiand South Africa Indiand Kenya Indiand Kenya Indiand Kenya Indiand Kenya Indonesia Kenya Indiand Kenya Indiand Kenya Indiand Kenya Indiand Indonesia Indiand Russia Indiand	Japan		
India	South Korea		
Singapore Thailand South Africa Kenya Nigeria Egypt Morocco Algeria Ethiopia Mexico Brazil Argentina Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Philippines Russia	China		
Thailand South Africa Kenya Nigeria Egypt Morocco Algeria Ethiopia Mexico Brazil Argentina Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	India		
South Africa O O Kenya O O Nigeria O O Egypt O O Morocco O O Algeria O O Ethiopia O O Mexico O O Brazil O O Argentina O O Chile O O Colombia O O New Zealand O O Greece O O Rwanda O O Uganda O O Serbia O O Saudi Arabia O O UAE O O Syria O O Indonesia O O Vietnam O O Philippines O O Russia O O	Singapore		
Kenya O Nigeria O Egypt O Morocco O Algeria O Ethiopia O Mexico O Brazil O Argentina O Chile O Colombia O New Zealand O Greece O Rwanda O Uganda O Serbia O Saudi Arabia O UAE O Syria O Indonesia O Vietnam O Philippines O Russia O	Thailand	0	
Nigeria Egypt Morocco Algeria Ethiopia Mexico Brazil Argentina Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	South Africa	0	0
Egypt Morocco Algeria Ethiopia Mexico Brazil Argentina Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Kenya	0	0
Morocco Algeria Ethiopia O Mexico Brazil Argentina Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia O O O O O O O O O O O O O O O O O O O	Nigeria	0	0
Algeria Ethiopia Mexico Brazil Argentina Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Phillippines Russia	Egypt	0	0
Ethiopia Mexico Brazil Argentina Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Phillippines Russia	Morocco	0	0
Mexico Brazil Argentina Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Algeria		
Brazil Argentina Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Ethiopia	0	0
Argentina Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Mexico		
Chile Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Brazil		
Colombia New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Argentina		
New Zealand Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Chile		
Greece Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Colombia		
Rwanda Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	New Zealand		
Uganda Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Greece	0	
Serbia Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Rwanda	0	0
Saudi Arabia UAE Syria Indonesia Vietnam Philippines Russia	Uganda	0	0
UAE Syria O Indonesia Vietnam Philippines Russia O Russia O O O O O O O O O O O O O O O O O O O	Serbia		
Syria O O O O O O O O O O O O O O O O O O O	Saudi Arabia		
Indonesia Vietnam Philippines Russia Indonesia Russia	UAE		
Indonesia Vietnam Philippines Russia Indonesia Russia		0	
Philippines O O O O O O O O O O O O O O O O O O O			\bigcirc
Philippines O O O O O O O O O O O O O O O O O O O			
Russia O	Philippines	0	
		0	0





- Targeted endoscopic screening in highincidence zones (e.g., southern Chile).
- Some primary care networks include H. pylori detection and treatment as part of GI symptom evaluation.

W

О Т

Weakness

- No national screening program for gastric cancer exists.
- Asymptomatic individuals rarely undergo routine upper GI screening.

Opportunity

- Establish risk-based screening protocols for individuals >40 years with family history or H. pylori history.
- Public-private partnerships for community screening drives could boost early detection.

- Low funding for mass screening infrastructure.
- Public hesitancy toward invasive procedures like endoscopy without clear symptoms.

Country	Gastric Cancer Screening
United States	Annual LDCT (50-80 years, high-risk smokers)
United Kingdom	LDCT for high-risk individuals (55-74 years)
Canada	LDCT for high-risk individuals (55-74 years)
Australia	No national program, high-risk groups advised LDCT
Germany	No national program, under evaluation
France	No national LDCT screening
Netherlands	Participating in European screening studies
Sweden	No national LDCT screening
Italy	Regional pilot LDCT screening
Spain	No national LDCT program
Poland	No national program
Japan	No national LDCT program
South Korea	LDCT for high-risk individuals (50-74 years)
China	No national LDCT program
India	No national LDCT program
Singapore	No national LDCT program
Saudi Arabia	No national LDCT program; some hospital-based opportunistic screening
UAE	No national LDCT program; early-stage pilot studies ongoing in select hospitals
Syria	No national LDCT program; screening not prioritized due to conflict
Malaysia	No program; high-risk CT pilots

Country	Gastric Cancer Screening
Courtery	dastric caricer screening
Thailand	No national LDCT program
South Africa	No national LDCT program
Kenya	No national LDCT program
Nigeria	No national LDCT program
Egypt	No national LDCT program
Morocco	No national LDCT program
Algeria	No national LDCT program
Ethiopia	No national LDCT program
Mexico	No national LDCT program
Brazil	No national LDCT program
Argentina	No national LDCT program
Chile	No national LDCT program
Colombia	No national LDCT program
New Zealand	No national LDCT program
Greece	No national LDCT program
Rwanda	No national LDCT program
Uganda	No national LDCT program
Serbia	No national LDCT program
Indonesia	No national LDCT program; opportunistic screening in private sector
Vietnam	No national LDCT program; early pilot screening studies in Hanoi and Ho Chi Minh
Philippines	No national LDCT program; feasibility and awareness programs under discussion
Russia	No formal national LDCT program; regional pilot screening programs in large cities